PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

Similar documents
PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

Table 1. Particle size distributions and peroxide levels of various superdisintegrants. D50 (μm) D10 (μm)

Pharma Ingredients & Services. Ludiflash. Technical Information

Kollidon SR: A polyvinyl acetate based excipient for DCsustained-release

Maximizing Roller Compaction Benefits with Proper Excipient Selection

Pharma & Food Solutions. ETHOCEL One of the Few Water-Insoluble Polymers Approved for Global Pharmaceutical Applications

NISSO HPC for Pharmaceutical Applications

Pharma Ingredients & Services. Soluplus. Technical Information. = Registered trademark of BASF group. July 2010 Supersedes issue dated May 2010

Formulation and Evaluation of Gastro retentive Bilayer Tablets- Glimepiride as Sustained Release and Lisinopril as Immediate Release

Roller Compaction: New trends, challenges and solutions

One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluation

Rajesh Kaza. et al /J. Pharm. Sci. & Res. Vol.1(4), 2009,

Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study

Model-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017

Quality by Design for ANDAs: An Example for Immediate-Release Dosage Forms

METHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow

Scientific and Regulatory challenges in Quality by Design (QbD) submissions

Implementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development. S Betterman 15Apr2015

Microcrystalline Cellulose, Colloidal Silicon Dioxide, Sodium Starch Glycolate, Sodium Stearyl Fumarate

Kollidon The Original Setting new standards in stability, purity and patient safety.

Balancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL

TABLETABILITY, COMPACTABILITY, AND COMPRESSIBILTY: WHAT S THE DIFFERENCE?

Preface... iii Contents...vii Contributors...xv. 1 Introduction to Hot-Melt Extrusion, Continuous Manufacturing: Scale-up via Hot-Melt Extrusion...

"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY

Research Article. Formulation and in-vitro evaluation of orodispersible tablets of olanzapine for the improvement of dissolution rate

CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE

QbD implementation in Generic Industry: Overview and Case-Study

Effect of Hydrophobic Polymers on the Gastro Retention Time and In vitro Release of Ciprofloxacin HCl from Co-matrix Tablets

Evaluation of rice husk as an excipient for the pharmaceutical industry

Technological aspects of Encapsulation via Melt Extrusion Technology

Formulation and in-vitro evaluation of pregabalin mini tablets for sustained release

Practical Guide to Hot-Melt Extrusion: Continuous Manufacturing and Scale-up

Product Quality Control of a HME Co-Extrudate Using a Raman Imaging Microscope

Thermal and Rheological Evaluation of Pharmaceutical Excipients for Hot Melt Extrusion

Notes. Plastic Behavior In The Compounding Twin Screw Extruder. Lesson 4. I. Screw Terminology. A. Length to Diameter Ratio (L/D ratio)

Formulation of Acetylsalicylic Acid Tablets for Aqueous Enteric Film Coating

Functionalized Calcium Carbonate (FCC) FCC: Newly developed structured minerals as multifunctional excipients

Effect of Formulation and Process Variables

Compounding and Processing Additives for Woodfiber-Plastic Composites

refreshing extrusion technology

Achieving Excellence in Continuous Manufacturing: Using Process Models for Process Development and Understanding Process Dynamics

SCIENTIFIC DISCUSSION

Design and Development of Polyethylene Oxide Based Matrix Tablets for Verapamil Hydrochloride

Computation of Solubility parameters using Molecular. dynamics simulation

USP Hypromellose Phthalate

PARALOID K-120ND Processing Aid for Vinyl Compounds

FORMULATION AND EVALUATION OF POLYMER EFFECT ON in-vitro KINETICS OF SUSTAINED RELEASE MATRIX TABLETS OF CARVEDILOL USING MODEL DEPENDENT METHODS

Formulation and in vitro evaluation of bosentan osmatic controlled release tablets

Novel Floating Pulsatile Approach for Chronotherapeutic Release of Indomethacin

Fluoroguard. General Overview. Polymer Additive

EXTRUSION TECHNOLOGY. Extruders and extrusion lines

RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products

Pelagia Research Library

Research Article. Quality by Design (QbD) Approach for Formulation Development of Hydralazine Hydrochloride Tablets

INTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES

International Journal of Pharmacy

Formulation and Evaluation of Oro-Dispersible Tablets Containing Meclizine Hydrochloride

Formulation, Evaluation and Optimization of Fast dissolving tablet containing Tizanidine Hydrochloride

Development of Advanced Structural Foam Injection Molding. Kye Kim. A thesis submitted in partial fulfillment of the requirements for the degree of

Pelagia Research Library. Design fabrication and characterization of controlled released tablets of Trimetazidine di hydrochloride

PHARMACEUTICAL MANUFACTURING

How to Identify Critical Quality Attributes and Critical Process Parameters

Pharma Ingredients & Services. Kollidon SR. Technical Information

Design and Evaluation of Sustained Release Tablets containing Solid dispersion of Ziprasidone hydrochloride

FORMULATION AND EVALUATION OF ALFUZOSIN HYDROCHLORIDE EXTENDED RELEASE TABLETS

DISSOLUTION TESTING OF GELS, TOPICAL CREAMS & OINTMENTS

Approaches to the formulation of poorly soluble drugs

Excipient Development at NCL

Shashank Tiwari et al /J. Pharm. Sci. & Res. Vol.3(10), 2011,

Quan Liu and Reza Fassihi. Department of Pharmaceutical Sciences, School of Pharmacy, Temple University, Philadelphia, USA

Regulatory Assessment

One Processing Technology Variable Applications. Gülden Yılmaz

THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION

3M Advanced Materials Division 3M TM. Boron Nitride Cooling Fillers Smart Coolness for Excellent Performance

Direct compression of cushion layered ethyl cellulose coated extended release pellets into rapidly disintegrating tablets

TASTE MASKING OF BITTER DRUG BY USING ION EXCHANGE RESIN

DIRECTLY COMPRESSIBLE MEDICATED CHEWING GUM (MCG) FOR STAYING ALERT

Public Assessment Report. Scientific discussion. Atovaquon/Proguanil HCl Sandoz 62.5/25 mg and 250/100 mg, film-coated tablets

Design and Dosage Form. Dr. Deny Susanti

Binder Optimization for the Production of Tungsten Feedstocks for PIM

Cocrystals: A Regulatory Perspective. Scott L. Childs Renovo Research

Fish Feed Production Systems

Proper Dispersion of Silberline Aluminum Pigments in Plastics

Figure 1. Standard spray congealing setup.

Pharmaceutical Sciences

Optimizing Extruder Controls, Part Two

Lifolit. Soft PVC processing guide

1. Master Batch Record Approvals Name Signature Date Originator

Dryflex WS H 2. O Hydrophilic Thermoplastic Elastomers

BCS Guidance and Biowaivers BCS Monographs

Improving Oral Bioavailability by Solid Dispersions: An OSPHENA (Ospemifene) Case Study

Developments in Small Scale Twin Screw Extruders for Color Development. Charlie Martin, Leistritz Extruson. Abstract. Background

Gelimat Technology. Ultrahigh-Speed Thermokinetic Mixing, Compounding & Fluxing. Processing Excellence in Motion DUSATEC DUSATEC, INC.

Formulation Development

Chemical Foaming Alternatives to Azodicarbonamide

Pharma Twin Screw Extruders 2010

Stability Report. Stability profile of. BIWG 98 SE tablets 40 mg SR of 133. This stability report comprises 133 pages.

Dow Pharma Solutions. ETHOCEL High Productivity (HP) Polymers Safe. Fast. Efficient.

REVIEW. E N H A N C I N G MELTING AND MIXING in a Twin-Screw Extruder. Capabilities. Page 1 of 5

Transcription:

PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-81 Page 1 of 5 Hot Melt Extrusion with Klucel hydroxypropylcellulose HPC for the Controlled Release of High Doses of a Highly Soluble Active Elanor Pinto, Audrey Pittman, Chris Hood, Courtney R. Usher, Scott D. Bradley, Divya Tewari, and Thomas Dürig Introduction Delivering high doses of highly soluble actives in matrix tablets is challenging as it necessitates the minimum addition of release controlling excipients and other process and formulation aids in order to limit tablet size for ease of swallowing. Typically maximum weights for swallowable tablets range from 8 to 1 mg. The granule and final tablet density also have to be considered when attempting to minimize unit dose volume. In this study, highly soluble Metformin Hydrochloride (METF) was chosen as a typical high dose compound (15 to 3 mg daily in a 12 hour dosing period). Since METF is typically administered with food and is mainly absorbed from the proximal small intestine [1], the aim of the study was to deliver a 6 to 75 mg dose over a period of 6-8 hours, with 6% released between 2 to 4 hours. This study investigates the feasibility of using hot melt extrusion (HME) as an alternative to wet granulation (WG) for the preparation of controlled release formulations of a highly soluble drug at high drug loads (75%). High molecular weight grades of Klucel hydroxypropylcellulose (HPC) were used as a thermoplastic, water soluble carrier and release controlling polymer. The efficacy of hot melt extrusion was assessed by comparing similar formulations prepared by wet granulation and direct compression. Experimental Methods Wet granulation. 1 kg batches comprising 75% Metformin (METF) and 25% Klucel HPC HF Pharm were wet granulated in a high shear mixer. After drying, milling, and lubrication, 1 mg tablets were precompressed at 3kN and compressed at 15kN on an instrumented Manesty Beta Press equipped with.75 x.343 caplet tooling. The press speed was 33 rpm. Tablet porosity (ε) was calculated as follows: ε = 1- Tablet Density / True density Tablet density was calculated from the tablet volume and mass. The True density of the granules before compression was measured by Helium pycnometry. Tablet dissolution was tested in USP apparatus I with 6.8 ph phosphate buffer. Direct Compression. 1 kg batches comprising 75% Metformin (METF) and 25% Klucel HPC HF Pharm were mixed in a V-blender for 15 minutes. Tabletting and dissolution studies were performed using the same conditions mentioned above. This work was presented at the American Association of Pharmaceutical Scientists, November 14 November 18, 21, New Orleans, Louisiana, USA. All statements, information and data presented herein are believed to be accurate and reliable, but are not to be taken as a guarantee, an express warranty, or an implied warranty of merchantability or fitness for a particular purpose, or representation, express or implied, for which Ashland and its subsidiaries assume legal responsibility. Registered trademark, Ashland or its subsidiaries, registered in various countries. Trademark, Ashland or its subsidiaries, registered in various countries. *Trademark owned by a third party. 212, Ashland. 1-212

Page 2 of 5 Hot Melt Extrusion. 1 kg batches of the above mentioned blend was hot melt extruded at a processing temperature of 165 o C and screw speed of 15 rpm using the Leistritz ZSE 18HP counter-rotating twin screw extruder without a die (Figure 1). Extrudrate was hammer milled and lubricated. Tabletting and dissolution studies were performed using the same conditions mentioned above. Figure 1. Extruder setup. The drug/polymer blend consisting of 75% Metformin HCl and 25% Klucel HPC HF was extruded without the use of a die and at the temperature settings and extruder settings mentioned below. Side view of extruder barrel Melt 1 2 3 4 5 6 7 8 Materials 1. Metformin HCl, marketed by Ria International, NJ. 2. Klucel HPC hydroxypropylcellulose, marketed by Ashland, Wilmington, DE 3. HyQual* magnesium stearate, NF, marketed by Mallinckrodt Inc., a Division of Tyco International, St. Louis, MO. Results and Discussion The METF tablets made by hot melt extrusion were more than two times stronger, smaller, and consequently less porous as compared to the analogous tablets made by wet granulation and direct compression (Table 1). The lower porosity of the extruded tablets is also readily seen from the tablet cross-section (Figure 2). The improved mechanical properties and smaller tablet size for the same weight of unit dose can be attributed to the intimate mixing of drug with polymer in the molten state and the substantial elimination of air in the extrudate and final tablet. In addition, the extrusion process also resulted in improved compactability and reduced elastic recovery as evidenced by the enhanced tablet strength and reduced friability. Table 1. Tablet physicals. Extrusion results in marked reduction of tablet porosity, increasing strength, and decreased drug release (burst) in early time phase. Unit Process Granule Density (g/ml) Tablet Volume (ml) Porosity (%) Tablet Strength (Kp) 3kN Pre-compression 15kN Main compression Extrusion 1.3.8 3.4 14.2 Wet Granulation 1.35.9 12.7 4. Direct Compression 1.35.9 15.3 5.

Page 3 of 5 Figure 2. Porosity of Metformin HCl tablets. The Scanning Electron Microscope (SEM) pictures of the crosssection of the tablets show that the tablets made by hot melt extrusion were a lot more dense and less porous. Extruded Wet Granulated Direct Compression The reduced porosity of the hot melt extruded METF tablets resulted in a dramatic improvement in the release retardation of METF as compared to wet granulated and direct compression tablets (Figure 3). The differences can be attributed to the lower porosity of the hot melt extruded tablets resulting in slower ingress of media into the tablet (Figures 4 and 5) and thus slower diffusion of dissolved drug out of the tablet in the early time phase (first 3 minutes). After this initial period a sufficiently strong gel layer envelops the tablet to control the further ingress of water into the system. Figure 3. Dissolution profile of Metformin HCl tablets. The extruded tablets resulted in greater drug release retardation (USP apparatus I, 6.8 ph phosphate buffer, 1 rpm). 1 % Metformin Released 8 6 4 2 75% METF, 25% Klucel HPC HF Direct Compression 75% METF, 25% Klucel HPC HF Wet Granulation 75% METF, 25% Klucel HPC HF Extruded Current (Without Die) 2 4 6 8 1 12 Time (hrs)

Page 4 of 5 Figure 4. Media uptake of Metformin HCl tablets. Tablets made by hot melt extrusion were the least porous of the three and hence had slower dissolution media penetration rate. The porosity of the porous surfaces were further illustrated by the rapidly changing and much lower contact angle for the wet granulated and direct compression tablets. Hours Extruded Wet Granulated Direct Compression Contact Angle 56.8 o o 38.8 o.5 1. Figure 5. Media uptake of Metformin HCl tablets. The tablets were submersed in a blue dye solution for 3 minutes and then dried overnight. Pictures of the cross sectional surfaces were then taken. Extruded Wet Granulated Direct Compression

Page 5 of 5 Accelerated stability studies were conducted on the extruded tablets at 4 o C and 75% RH. Table 2 shows that the tablets are chemically stable even after 12 weeks of testing. Table 2: Drug stability of high dose extruded tablets. Tablets stored in sealed HDPE bottles at 4 o C, 75% RH. Tablet formulation comprised of 75% METF and 4% Klucel HF HPC. Percent drug by HPLC Day Week 1 Week 2 Week 4 Week 8 Week 12 96.4 96.6 96.3 96.4 96.5 96.2 In addition, Figure 6 shows that the dissolution profiles remained similar under accelerated storage conditions. Figure 6. Dissolution stability of high dose extruded tablets. Tablets stored in sealed HDPE bottles at 4 o C, 75% RH. Dissolution was performed using the USP apparatus 1, 6.8 ph phosphate buffer at 1 rpm. 1 8 % Metformin Released 6 4 2 75% METF, 25% Klucel TM HPC HF D W1 W2 (f 2 = 93.5) (f 2 = 97.7) W4 (f 2 = 89.4) W8 (f 2 = 92.) W12 (f 2 = 91.7) 2 4 6 8 1 12 Time (hrs) Conclusion By using Klucel HPC as a thermoplastic release retarding excipient, it was possible to produce controlled release METF tablets with very high drug loading (up to 75%). These tablets had improved compactability and mechanical properties, resulting in smaller tablets with significantly enhanced release retardation as compared to the equivalent composition prepared by wet granulation and direct compression. A further advantage of this processing method is that continuous granulation is possible. References 1. G.Gusler, J. Gorsline, et. al., Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers, J Clin Pharmacol. 21; 41: 655-661